142 related articles for article (PubMed ID: 37567572)
1. Galectin-3 is able to differentiate dogs with myxomatous mitral valve disease from healthy control dogs.
Kim YM; Kim SW; Kim JH
Am J Vet Res; 2023 Sep; 84(9):. PubMed ID: 37567572
[TBL] [Abstract][Full Text] [Related]
2. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
[TBL] [Abstract][Full Text] [Related]
3. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
Kim HJ; Kim J; Kim S; Kim HJ
BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
[TBL] [Abstract][Full Text] [Related]
4. Plasma and platelet serotonin concentrations in healthy dogs and dogs with myxomatous mitral valve disease.
Mangklabruks T; Surachetpong SD
J Vet Cardiol; 2014 Sep; 16(3):155-62. PubMed ID: 25127665
[TBL] [Abstract][Full Text] [Related]
5. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
[TBL] [Abstract][Full Text] [Related]
6. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
Mangkhang K; Punyapornwithaya V; Tankaew P; Pongkan W; Chattipakorn N; Boonyapakorn C
Pol J Vet Sci; 2018 Dec; 21(4):673-680. PubMed ID: 30605282
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of endothelial cell-specific molecule-1 as a biomarker of glycocalyx damage in canine myxomatous mitral valve disease.
Hong HJ; Oh YI; Park SM; An JH; Kim TH; Chae HK; Seo KW; Youn HY
BMC Vet Res; 2022 Jul; 18(1):261. PubMed ID: 35790968
[TBL] [Abstract][Full Text] [Related]
8. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
Rešetar Maslov D; Farkaš V; Rubić I; Kuleš J; Beletić A; Beer Ljubić B; Šmit I; Mrljak V; Torti M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108311
[TBL] [Abstract][Full Text] [Related]
9. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
[TBL] [Abstract][Full Text] [Related]
10. Plasma and serum serotonin concentrations and surface-bound platelet serotonin expression in Cavalier King Charles Spaniels with myxomatous mitral valve disease.
Cremer SE; Kristensen AT; Reimann MJ; Eriksen NB; Petersen SF; Marschner CB; Tarnow I; Oyama MA; Olsen LH
Am J Vet Res; 2015 Jun; 76(6):520-31. PubMed ID: 26000599
[TBL] [Abstract][Full Text] [Related]
11. Iron parameters analysis in dogs with myxomatous mitral valve disease.
Kumiega E; A Kobak K; Noszczyk-Nowak A; Kasztura M
BMC Vet Res; 2024 May; 20(1):210. PubMed ID: 38762716
[TBL] [Abstract][Full Text] [Related]
12. Serum serotonin concentration is associated with severity of myxomatous mitral valve disease in dogs.
Ljungvall I; Höglund K; Lilliehöök I; Oyama MA; Tidholm A; Tvedten H; Häggström J
J Vet Intern Med; 2013; 27(5):1105-12. PubMed ID: 23865457
[TBL] [Abstract][Full Text] [Related]
13. Cardiac troponin I is associated with severity of myxomatous mitral valve disease, age, and C-reactive protein in dogs.
Ljungvall I; Höglund K; Tidholm A; Olsen LH; Borgarelli M; Venge P; Häggström J
J Vet Intern Med; 2010; 24(1):153-9. PubMed ID: 20002554
[TBL] [Abstract][Full Text] [Related]
14. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
Ogawa M; Hori Y; Kanno N; Iwasa N; Toyofuku T; Isayama N; Yoshikawa A; Akabane R; Sakatani A; Miyakawa H; Hsu HH; Miyagawa Y; Takemura N
J Vet Med Sci; 2021 Apr; 83(4):705-715. PubMed ID: 33551383
[TBL] [Abstract][Full Text] [Related]
15. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
[TBL] [Abstract][Full Text] [Related]
16. Biologic variability of cardiac troponin I in healthy dogs and dogs with different stages of myxomatous mitral valve disease using standard and high-sensitivity immunoassays.
Winter RL; Saunders AB; Gordon SG; Miller MW; Fosgate GT; Suchodolski JS; Steiner JM
Vet Clin Pathol; 2017 Jun; 46(2):299-307. PubMed ID: 28449360
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of the utility of shock index to determine the presence of congestive heart failure in dogs with myxomatous mitral valve disease (2019-2021): 98 cases.
Matson H; Llewellyn EA
J Vet Emerg Crit Care (San Antonio); 2024; 34(3):231-237. PubMed ID: 38809224
[TBL] [Abstract][Full Text] [Related]
18. Utility of cardiac MRI to diagnose myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
Clark WA; Winter RL; Aarnes TK; Green EM; Mikrut K; Ruz P; Addison D; Rhinehart JD; Schober KE; Friel HT
Am J Vet Res; 2022 Aug; 83(10):. PubMed ID: 35905145
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease.
Mihara K; Kanemoto I; Sato K; Yasuhira Y; Watanabe I; Misumi K
J Vet Cardiol; 2021 Oct; 37():8-17. PubMed ID: 34507141
[TBL] [Abstract][Full Text] [Related]
20. Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio.
Ku D; Chae Y; Kim C; Koo Y; Lee D; Yun T; Chang D; Kang BT; Yang MP; Kim H
Am J Vet Res; 2023 Jun; 84(6):. PubMed ID: 37024099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
